Please assess the completion status of the following clinical trial:

Trial Title: A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed study B2061032 and who in the investigator's opinion, would benefit from long term treatment with DVS SR~* Willingness and ability to comply with scheduled visits, treatment plan, and procedures~Exclusion Criteria:~* Requires precaution against suicide~* Not in generally healthy medical condition~* Poor compliance with study drug or study procedures during participation in study B2061032

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine Succinate Sustained-Release (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).